Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEEPsAKE 1: risankizumab versus placebo in active psoriatic arthritis after inadequate response or intolerance to at least one csDMARD
2023-505478-14-00Phase 3Authorised
- Sponsor
- AbbVie Inc.
- Start
- May 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 36
01
Overview
Phase 3, randomised, double-blind trial in psoriatic arthritis (PsA) comparing Risankizumab with Placebo (2 arms). Primary endpoint: ACR20 response at Week 24. Planned start May 2019; status: authorised.
02
Drugs
risankizumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2023-505478-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505478-14-00.